Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants With Parkinson's Disease and Apathy

NCT07461220 is registered in ClinicalTrials.gov with Integrative Research Laboratories AB as lead sponsor.

NCT NCT07461220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07461220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants With Parkinson's Disease and Apathy
Lead sponsor
Integrative Research Laboratories AB
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 18, 2026
Completion date
May 31, 2027
Enrollment
75 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

apathy, parkinson disease (disorder), safety